TD Cowen Maintains Buy Rating on LENZ Therapeutics, Cuts Target to $45
TD Cowen maintained its Buy rating on LENZ Therapeutics and lowered its price target to $45 from $50.
Related stories
BOJ Says ETF Holdings Sales Would Take About 43 Years
The BOJ says completing sales of its ETF holdings would take about 43 years, down from a previous estimate of about 112 years.
L impact | EQUITY | Oct 30, 2026, 03:08 AM UTC
Nikkei futures extend losses, down 2.8% at 62,910
Nikkei futures were down 2.8% at 62,910, versus a 2.5% decline previously, after the BOJ outcome.
M impact | EQUITY | Oct 30, 2026, 03:07 AM UTC
Nikkei Futures Extend Decline, Down 2.9% After BOJ Decision
M impact | EQUITY | Oct 30, 2026, 03:07 AM UTC
Q2 Results Live Updates: Suzlon, Trent react to numbers; RIL, Sun Pharma, BEL, report today
Q2 Results Live Updates: The final trading day of the week will bring in a plethora of result reactions and plenty of earnings as well from Nifty 50 and broader market companies. R
H impact | EQUITY | Oct 30, 2026, 03:06 AM UTC
BOJ to Sell ETF Holdings at About 0.1% of Market Trading Value
M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC
Nikkei Futures Down 2.6% After BOJ Decision
Nikkei futures were last down 2.6%, largely unmoved by the BOJ decision.
M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC